IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 34 cases where IBRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +2.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 209 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Aroon Indicator entered an Uptrend today. In 117 of 123 cases where IBRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The 10-day RSI Indicator for IBRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 20 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRX as a result. In 87 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for IBRX turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 45 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
IBRX moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.526) is normal, around the industry mean (2.978). P/E Ratio (-8.863) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Aroon Indicator for QTTB entered a downward trend on October 19, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 235 similar instances where the Aroon Indicator formed such a pattern. In 218 of the 235 cases the stock moved lower. This puts the odds of a downward move at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTTB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where QTTB's RSI Indicator exited the oversold zone, 22 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for QTTB just turned positive on October 08, 2026. Looking at past instances where QTTB's MACD turned positive, the stock continued to rise in 36 of 38 cases over the following month. The odds of a continued upward trend are 90%.
Following a +8.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTTB advanced for three days, in 212 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
QTTB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. QTTB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.190) is normal, around the industry mean (2.978). P/E Ratio (2.481) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (3.034) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTTB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IBRX | QTTB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 39 | 3 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 9 Undervalued | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 16 | |
PRICE GROWTH RATING 1..100 | 50 | 50 | |
P/E GROWTH RATING 1..100 | 55 | 35 | |
SEASONALITY SCORE 1..100 | 45 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IBRX's Valuation (9) in the Biotechnology industry is somewhat better than the same rating for QTTB (74) in the null industry. This means that IBRX’s stock grew somewhat faster than QTTB’s over the last 12 months.
IBRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as QTTB (100) in the null industry. This means that IBRX’s stock grew similarly to QTTB’s over the last 12 months.
QTTB's SMR Rating (16) in the null industry is significantly better than the same rating for IBRX (100) in the Biotechnology industry. This means that QTTB’s stock grew significantly faster than IBRX’s over the last 12 months.
QTTB's Price Growth Rating (50) in the null industry is in the same range as IBRX (50) in the Biotechnology industry. This means that QTTB’s stock grew similarly to IBRX’s over the last 12 months.
QTTB's P/E Growth Rating (35) in the null industry is in the same range as IBRX (55) in the Biotechnology industry. This means that QTTB’s stock grew similarly to IBRX’s over the last 12 months.
| IBRX | QTTB | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 71% |
| Stochastic ODDS (%) | 1 day ago 88% | 1 day ago 87% |
| Momentum ODDS (%) | 1 day ago 89% | N/A |
| MACD ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 86% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 88% |
| Advances ODDS (%) | 5 days ago 87% | 8 days ago 87% |
| Declines ODDS (%) | 1 day ago 88% | 4 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 90% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IBRX’s FA Score shows that 1 FA rating(s) are green while QTTB’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IBRX’s TA Score shows that 4 TA indicator(s) are bullish while QTTB’s TA Score has 5 bullish TA indicator(s).
IBRX (@Biotechnology) experienced а -16.80% price change this week, while QTTB (@Biotechnology) price change was -10.87% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.86%. For the same industry, the average monthly price growth was -18.66%, and the average quarterly price growth was -19.56%.
IBRX is expected to report earnings on Nov 05, 2026.
QTTB is expected to report earnings on Nov 05, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AIO | 23.50 | 0.35 | +1.51% |
| Virtus Artificial Intelligence & Technology Opportunities Fund | |||
| SCEP | 24.89 | 0.15 | +0.62% |
| Sterling Capital Hedged Equity Premium Income ETF (SCEP) | |||
| SLJY | 26.27 | -0.15 | -0.57% |
| Amplify SILJ Junior Silver Miners Covered Call ETF (SLJY) | |||
| VNQ | 90.71 | -1.05 | -1.14% |
| Vanguard Real Estate ETF (VNQ) | |||
| SMHB | 3.01 | -0.15 | -4.76% |
| ETRACS 2xMonthly Pay Leveraged US Small Cap High Dividend ETN Series B (SMHB) | |||
A.I.dvisor indicates that over the last year, QTTB has been loosely correlated with CLRB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if QTTB jumps, then CLRB could also see price increases.
| Ticker / NAME | Correlation To QTTB | 1D Price Change % | ||
|---|---|---|---|---|
| QTTB | 100% | +3.59% | ||
| CLRB - QTTB | 62% Loosely correlated | -1.75% | ||
| MESO - QTTB | 51% Loosely correlated | -10.02% | ||
| STOK - QTTB | 49% Loosely correlated | +2.69% | ||
| IBRX - QTTB | 40% Loosely correlated | -8.28% | ||
| ANAB - QTTB | 39% Loosely correlated | +5.64% | ||
More | ||||